Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer

INCLUSION CRITERIA: * Patients ≥ 3 and \< 21 years of age at the time of study registration. * Patients newly diagnosed with Wilm's tumor and scheduled to receive at least 9 consecutive weeks of chemotherapy with a vincristine-containing regimen. * Patients newly diagnosed with rhabdomyosarcoma and scheduled to receive at least 9 consecutive weeks of chemotherapy with a vincristine-containing regimen. * Patients newly diagnosed with ALL and scheduled to receive 4 consecutive weeks of chemotherapy with a vincristine-containing regimen with accompanying steroid therapy. * Patients newly diagnosed with Non- Hodgkins Lymphoma (NHL) and scheduled to receive 4 consecutive weeks of chemotherapy with a vincristine-containing regimen with accompanying steroid therapy. * Patients with no underlying neuromuscular disease or peripheral neuropathy EXCLUSION CRITERIA: * Abnormal baseline peripheral neurologic exam (i.e. or peripheral neuropathy) * Patients with: * seizure disorders * primary intracranial malignancy * family history of Charcot Marie Tooth Disease * a recent history of GuillianBarré26 * Patients receiving concomitant itraconazole are at risk for increased vincristine toxicity and therefore are ineligible. * Patients who are regularly using laxatives or stool softeners for constipation at the time of enrollment are not eligible to participate in the study. Likewise, since prevention of neuro-constipation will be evaluated, patients with an ongoing history of constipation t…